467 Studies Now Enrolling
A Single Arm, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NM-IL-12 (RHUIL 12) in Patients with Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)
A study for patients with Cutaneous T Cell Lymphoma (CTCL) using study drug NM-IL-12
| Sponsor: | Neumedicines |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ5717 |
| U.S. Govt. ID: | NCT02542124 |
| Contact: | Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu |
Additional Study Information:
This is a research study to test the effectiveness of NM-IL-12 an experimental drug, in combination with low dose Total Skin Electron Beam Therapy (TSEBT) for treatment of Cutaneous T Cell Lymphoma. The study will enroll 10 subjects age 18 years and older.Treatment will consist of 3 weeks of TSEBT, and up to 27 weeks of NM-IL-12 treatment starting from day 2 of TSEBT. A 4 week follow-up period will take place following the last treatment of NM-IL-12. Measurements of general safety and toxicity will be used to determine the effectiveness of the drug.
This study is closed
